Accordingly to our findings, AKT can be activated by Nrf2, leading to the degradation of p21, suggesting Nrf2 promoted HCC progression by activation of the AKT/p21 pathway. The gene discussed is NFE2L2; the disease is hepatocellular carcinoma.